SNSS:NASDAQ

Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The company has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.

Expert Comments:

"Sunesis Pharmaceuticals Inc. had a major inflection point with the readout of the Phase 3 VALOR trial examining Qinprezo (vosaroxin) in acute myeloid leukemia. . .using a prestratified grouping, the trial achieved significance. . .we think there is opportunity for the FDA to accept a new drug application filing from the company given the data generated in the trial and the abysmal clinical trial history of drugs for this disease. . .this, we believe, will be an opportunity to reset the valuation. Whether the FDA would be willing to approve the drug is a very large question mark. . .however, based on other clinical scenarios that we have identified, we think there is such an opportunity, and that drives our interest in the shares in spite of the very binary nature of the next inflection point." read more >

Mara Goldstein, Cantor Fitzgerald (1/6/15)
"We believe the most important near term inflection point for Sunesis Pharmaceuticals Inc. shares will be the outcome of a meeting with the FDA to discuss Valor trial results and the potential for NDA filing. The shares, we believe, largely reflect a bearish scenario, while we believe that FDA will agree to review an NDA filing. Such an outcome could prompt share price revaluation."

Joseph Pantginis, ROTH Capital Partners (12/15/14)
"We believe Sunesis Pharmaceuticals Inc. shares will perform well in 2015. . .a meeting with the FDA is planned for Q1/15 and following that, we predict an advisory committee resulting in a modestly positive vote supporting FDA approval in specific subgroups. We are upgrading our rating to Buy."

Mara Goldstein, Cantor Fitzgerald (12/10/14)
"We are upgrading Sunesis Pharmaceuticals Inc. to a Buy. . .we believe that the analysis presented using prestratified log rank analytics is robust enough to warrant discussion with the FDA and possibly NDA filing. If our belief is correct that the FDA is willing to review an NDA, we expect the shares to be revalued."

Joseph Pantginis, ROTH Capital Partners (11/11/14)
"Sunesis Pharmaceuticals Inc. reported Q3/14 results posting EPS of $0.25 versus our estimate of $0.07 and a consensus estimate of $0.17."

Experts Commenting on This Company


The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
 
Totality of VALOR data shows compelling risk-benefit trade-off in disease with significant unmet need
 
Relapsed/refractory AML is a significant commercial opportunity with no approved agents
 
Our kinase inhibitor pipeline is poised to progress to the clinic in 2015 and 2016
catalyst Calendar